» Articles » PMID: 14645601

Folate Receptor Alpha and Caveolae Are Not Required for Ebola Virus Glycoprotein-mediated Viral Infection

Overview
Journal J Virol
Date 2003 Dec 4
PMID 14645601
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Folate receptor alpha (FRalpha) has been described as a factor involved in mediating Ebola virus entry into cells (6). Furthermore, it was suggested that interaction with FRalpha results in internalization and subsequent viral ingress into the cytoplasm via caveolae (9). Descriptions of cellular receptors for Ebola virus and its entry mechanisms are of fundamental importance, particularly with the advent of vectors bearing Ebola virus glycoprotein (GP) being utilized for gene transfer into cell types such as airway epithelial cells. Thus, the ability of FRalpha to mediate efficient entry of viral pseudotypes carrying GP was investigated. We identified cell lines and primary cell types such as macrophages that were readily infected by GP pseudotypes despite lacking detectable surface FRalpha, indicating that this receptor is not essential for Ebola virus infection. Furthermore, we find that T-cell lines stably expressing FRalpha are not infectible, suggesting that FRalpha is also not sufficient to mediate entry. T-cell lines lack caveolae, the predominant route of FRalpha-mediated folate metabolism. However, the coexpression of FRalpha with caveolin-1, the major structural protein of caveolae, was not able to rescue infectivity in a T-cell line. In addition, other cell types lacking caveolae are fully infectible by GP pseudotypes. Finally, a panel of ligands to and soluble analogues of FRalpha were unable to inhibit infection on a range of cell lines, questioning the role of FRalpha as an important factor for Ebola virus entry.

Citing Articles

Sphingosine Kinases Promote Ebola Virus Infection and Can Be Targeted to Inhibit Filoviruses, Coronaviruses, and Arenaviruses Using Late Endocytic Trafficking to Enter Cells.

Stewart C, Bo Y, Fu K, Chan M, Kozak R, Apperley K ACS Infect Dis. 2023; 9(5):1064-1077.

PMID: 37053583 PMC: 10186378. DOI: 10.1021/acsinfecdis.2c00416.


Pseudotyped Viruses for Marburgvirus and Ebolavirus.

Zhang L, Liu S, Wang Y Adv Exp Med Biol. 2023; 1407:105-132.

PMID: 36920694 DOI: 10.1007/978-981-99-0113-5_6.


Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: successful targets against some infectious diseases.

Shamshad H, Bakri R, Mirza A Mol Biol Rep. 2022; 49(7):6659-6691.

PMID: 35253073 PMC: 8898753. DOI: 10.1007/s11033-022-07266-8.


Mechanisms of Immune Evasion by Ebola Virus.

Bhattacharyya S Adv Exp Med Biol. 2021; 1313:15-22.

PMID: 34661889 DOI: 10.1007/978-3-030-67452-6_2.


Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules.

Fanunza E, Frau A, Corona A, Tramontano E Annu Rep Med Chem. 2020; 51:135-173.

PMID: 32287476 PMC: 7112331. DOI: 10.1016/bs.armc.2018.08.004.


References
1.
Niyogi K, Hildreth J . Characterization of new syncytium-inhibiting monoclonal antibodies implicates lipid rafts in human T-cell leukemia virus type 1 syncytium formation. J Virol. 2001; 75(16):7351-61. PMC: 114970. DOI: 10.1128/JVI.75.16.7351-7361.2001. View

2.
Martin J, Wharton S, Lin Y, Takemoto D, Skehel J, Wiley D . Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology. 1998; 241(1):101-11. DOI: 10.1006/viro.1997.8958. View

3.
Simmons G, Baribaud F, Netter R, Bates P . Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol. 2002; 76(5):2518-28. PMC: 153797. DOI: 10.1128/jvi.76.5.2518-2528.2002. View

4.
Bavari S, Bosio C, Wiegand E, Ruthel G, Will A, Geisbert T . Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med. 2002; 195(5):593-602. PMC: 2193767. DOI: 10.1084/jem.20011500. View

5.
Lineberger J, Danzeisen R, Hazuda D, Simon A, Miller M . Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol. 2002; 76(7):3522-33. PMC: 136010. DOI: 10.1128/jvi.76.7.3522-3533.2002. View